Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the oncology medicines that inhibit deoxyribonucleic acid damage repair and cause cancer cell death in specific subsets of cancer patients through a therapeutic strategy known as synthetic lethality. Co.'s primary program, CYT-0851, was identified through a phenotypic screening strategy that exploited a synthetic lethality between cytidine deaminases (CD) overexpression and homologous recombination inhibition. The screen was designed to select for compounds that induced synthetic lethality in CD-overexpressing cancer cells while sparing normal cells. The CYT stock yearly return is shown above.
The yearly return on the CYT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|